Resource center

Press Release

Genovac Enters Exclusive Licensing Agreement with Pfizer for Therapeutic Antibody Candidates

Pfizer to obtain exclusive worldwide rights to develop and commercialize antibodies from Genovac academic collaboration Fargo, North Dakota, USA, September…

• September 19, 2023

View

Press Release

Public-Private Collaboration Takes Aim at Hard-to-Target Cancers

Fargo, N.D., USA (3/13/2023) – Genovac, a Fargo based contract research and manufacturing organization (CRO/CMO) that discovers, develops, and manufactures…

• March 13, 2023

View

Press Release

Genovac further enhances its antibody discovery services with the ENPICOM IGX Platform

Genovac will use ENPICOM’s world-leading cloud platform to accelerate and improve antibody discovery and early de-risking of development for clients.

• May 2, 2022

View

Press Release

Genovac Acquires the Carterra LSA^® Instrument to Enable State-of-the-Art Antibody Screening and Characterization Services

Genovac becomes Carterra’s 100th LSA placement throughout the world. Fargo, North Dakota and Salt Lake City, Utah — April 20,…

• April 20, 2022

View

Press Release

Genovac to Present Innovations in Antibody Discovery Against Challenging Targets at Festival of Biologics in San Diego, March 9-11

Fargo, North Dakota, Mar 7, 2022 — Genovac, a contract research and manufacturing organization specializing in antibody discovery against challenging…

• March 8, 2022

View

Press Release

Genovac to Present Latest Innovations in Antibody Discovery Against Difficult Targets at Antibody Engineering & Therapeutics Conference in San Diego

Fargo, North Dakota, Dec. 13, 2021 — Genovac, a contract research and manufacturing organization specializing in antibody discovery against challenging…

• December 13, 2021

View

Press Release

Genovac Adds Third Berkeley Lights Beacon®, Now Offers Cell Line Development

Genovac Becomes the First Contract Research Organization (CRO) to Leverage the Beacon Technology for Both Antibody Discovery and Cell Line…

• October 5, 2021

View

Article

Drug Discovery World: “Berkeley Lights: Improving antibody discovery”

Time can be the most valuable asset in the drug and therapeutic development processes, especially in situations like the COVID-19…

• May 27, 2021

View

Article

Forbes: “Meet the Collaboration Solving Some of Antibody Discovery’s Toughest Problems”

Today’s biotechnology scientists and companies are focused more on working together in the drug and therapy development process to benefit…

• May 26, 2021

View

Press Release

Leland Joins Genovac as Vice President of Characterization and Production

Fargo, N.D. (May 4, 2021) – Pete Leland, a 20-year veteran of the biotechnology industry, has joined Genovac Antibody Discovery,…

• May 4, 2021

View

Press Release

Genovac Antibody Discovery Launches in NDSU Research and Technology Park

Genovac Fargo Fargo, N.D. (April 26, 2021) – A new biotechnology firm has chosen the North Dakota State Research and…

• April 26, 2021

View

Article

The Forum: “Fargo Biotech Firm is a Global Leader in Finding Antibodies and Turning Them Into New Drugs”

The Forum, Fargo, N.D., recently featured Genovac Antibody Discovery’s launch in the North Dakota State University Research & Technology Park,…

• April 26, 2021

View

Webinar

Tackle Difficult Targets by Accessing Broad B Cell Diversity

Genovac Research Scientist Patricia Odermatt and Anupam Singhal of Berkeley Lights talk for Digital Week’s Webcast Series on Antibodies, next-generation…

• March 3, 2021

View

Webinar

GEN Genetic Engineering & Biotechnology News Webinar

On November 19 2020 Genovac took part in a webinar hosted by GEN.  Panelists from Genovac presented case studies on…

• November 9, 2020

View